Nanoparticle‐Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer‐Associated Cachexia-Reference-Cited by-同舟云学术

Nanoparticle‐Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer‐Associated Cachexia

Published:2022-09-13 Issue:44 Volume:18 Page:2204436
ISSN:1613-6810
Container-title:Small
language:en
Short-container-title:Small

Author:

Korzun Tetiana¹²³⁴^ORCID,Moses Abraham S.¹^ORCID,Kim Jeonghwan¹,Patel Siddharth¹,Schumann Canan¹,Levasseur Peter R.⁴,Diba Parham³⁴,Olson Brennan³⁴^ORCID,Rebola Katia Graziella De Oliveira⁵^ORCID,Norgard Mason⁴,Park Youngrong¹^ORCID,Demessie Ananiya A.¹,Eygeris Yulia¹^ORCID,Grigoriev Vladislav¹⁴,Sundaram Subisha¹⁴,Pejovic Tanja⁶,Brody Jonathan R.⁵,Taratula Olena R.¹,Zhu Xinxia⁴,Sahay Gaurav¹,Marks Daniel L.⁴⁵⁷,Taratula Oleh¹²^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences College of Pharmacy Oregon State University 2730 S Moody Avenue Portland OR 97201 USA

2. Department of Biomedical Engineering Oregon Health & Science University 3303 SW Bond Avenue Portland OR 97239 USA

3. Medical Scientist Training Program Oregon Health & Science University 3181 SW Sam Jackson Park Road Portland OR 97239 USA

4. Papé Family Pediatric Research Institute Oregon Health & Science University SW Sam Jackson Park Rd, Mail Code L481 Portland OR 97239 USA

5. Knight Cancer Institute Oregon Health & Science University 2720 S Moody Avenue Portland OR 97201 USA

6. Departments of Obstetrics and Gynecology and Pathology Oregon Health & Science University 3181 SW Sam Jackson Park Road Portland OR 97239 USA

7. Brenden‐Colson Center for Pancreatic Care Oregon Health & Science University 2730 S Moody Avenue Portland OR 97201 USA

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/smll.202204436

Reference78 articles.

1. Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes

2. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer

3. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highlighting the idea of exerkines in the management of cancer patients with cachexia: novel insights and a critical review;BMC Cancer;2023-09-20

2. Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues;Small;2023-09-13

3. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers;Small;2023-07-30

4. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies;Frontiers in Oncology;2023-06-28

5. Functional Assessment of Therapy Tools for Cancer Cachexia: A Review;CURRENT TOPICS IN NUTRACEUTICAL RESEARCH;2023-04-18